- Current clinical trials of gene and cell therapy for sight loss
- Gene and cell therapies for inherited sight loss
- Gene and cell therapies for age-related macular degeneration (AMD)
- Gene therapy for diabetic eye disease
- Gene therapy for uveitis
- Gene therapy for corneal disease
Follow us (click an image below)
EyeTherapy Blog News
Registration for Retina Day 2015 now open!
Wed, 10 Jun 2015 11:37:25 +0000
It’s that time once agin for our annual research day for patients and the public. Retina Day 2015 is a free, one day event is organised by the Gene and Cell Therapy Group, UCL Institute of Ophthalmology and NIHR Moorfields Biomedical Research Centre. Come along to: * Hear about some of the latest innovations in research […]Read more...
UCL Gene Therapy Trial shows Benefit for up to Three Years After Treatment
Tue, 05 May 2015 14:44:39 +0000
We are delighted to be able to announce that yesterday, Monday 4th May, the long-term results of our RPE65 gene therapy trial for Leber Congenital Amaurosis Type 2 (LCA2) were published in the prestigious New England Journal of Medicine. Begun in 2007, this was the world’s first-in-human trial of gene therapy to treat an inherited […]Read more...
UCL researchers solve a major riddle of retinal degeneration research!
Mon, 26 Jan 2015 10:11:36 +0000
Today a paper published in Nature Communications from the Gene and Cell Therapy Group at the UCL Institute of Ophthalmology has shed light on why, until now, it has not been possible to effectively restore vision in rd1 mice – the world’s major model for retinitis pigmentosa (RP). The rd1 mouse is a model of […]Read more...
Gene therapy for uveitis
Uveitis is a leading cause of sight loss amongst those of working age. Find out about how you can support our work and help develop effective therapies.
Uveitis is a group of conditions in which the immune system attacks the body's own cells, leading to damaging inflammation and loss of sight. The eye's local immune system is normally tightly regulated by a balance of cells and molecules that prevent large-scale inflammation; caused by many different triggers depending on whether the front of the back of the eye is affected, uveitis results from a failure of this tight regulation.
Uveitis is a common condition for which existing treatments have
limitations - they are short-acting and are often systemically delivered, and chronic use can have significant side-effects. We are therefore developing longer-acting, locally-administered treatments based on viral gene therapy.
We have shown that delivering genes that help control the immune system locally in the eye can prevent the most damaging types of inflammation seen in models of uveitis, and are improving the effectiveness of gene therapy for uveitis through ongoing studies.
- Collaborator: Andrew Dick
Page last modified on 03 dec 12 11:11